7 Hills Pharma LLC
Integrin agonist molecules for cancer immunotherapy
- Sector
- Biotech
- Headquarters
- Houston, TX
- Latest Form D
- $1M, Jul 2024
- Total capital
- $17.5M
- Federal grants
- $16.5M
- 20 awards · 2016–2024
- Rank in peer group#411 of 514
- Private capital raised
- $1M
- 1 Form D · last Jul 2024
- 27 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 4 pending · first 2024
- Rank in peer group#186 of 514
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · 7HP349, an Integrin Activator to Treat Patients With anti-PD-1 Resistant Solid Tumors$999K
- Private capital raisedForm D · SEC · 1st filing$1M
- Federal grantHealth and Human S · Phase II · Integrin activator-adjuvanted DNA vaccine against Trypanosoma cruzi infection$998K
- Federal grantHealth and Human S · Phase II · 7HP349, an oral integrin activator to augment effectiveness of pre-exposure influenza vaccination$953K
- Federal grantHealth and Human S · Phase II · 7HP349, an Integrin Activator to Treat Patients With anti-PD-1 Resistant Solid Tumors$999K
- Federal grantHealth and Human S · Phase II · Integrin activator-adjuvanted DNA vaccine against Trypanosoma cruzi infection$998K
- Federal grantHealth and Human S · Phase II · 7HP349, an oral integrin activator to augment effectiveness of pre-exposure influenza vaccination$928K
Show 14 earlier federal awards
- Federal grantHealth and Human S · Phase II · Integrin activator-adjuvanted DNA vaccine against Trypanosoma cruzi infection$999K
- Federal grantHealth and Human S · Phase II · Development of 7HP349, an oral integrin activator to enhance therapeutic responses to immune checkpoint inhibitors$1M
- Federal grantHealth and Human S · Phase I · Integrin Activation to Augment SARS-CoV-2 Vaccination$298K
- Federal grantHealth and Human S · Phase II · A small molecule integrin activator to enhance cord blood transplant$929K
- Federal grantHealth and Human S · Phase II · Development of 7HP349, an oral integrin activator to enhance therapeutic responses to immune checkpoint inhibitors$984K
- Federal grantHealth and Human S · Phase II · A small molecule integrin activator to enhance cord blood transplant$936K
- Federal grantHealth and Human S · Phase II · Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer$1M
- Federal grantHealth and Human S · Phase I · Integrin Activation as a Treatment for Leukocyte Adhesion Deficiencies$243K
- Federal grantHealth and Human S · Phase I · Integrin Activation as a Treatment for Leukocyte Adhesion Deficiencies$243K
- Federal grantHealth and Human S · Phase II · Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer$2M
- Federal grantHealth and Human S · Phase II · Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer$1.0M
- Federal grantHealth and Human S · Phase I · A small molecule integrin activator to enhance cord blood transplant$296K
- Federal grantHealth and Human S · Phase I · Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer$314K
- Federal grantHealth and Human S · Phase I · Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer$314K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
97months
from 7 Hills Pharma LLC’s first federal award to its first private round.
- First federal award · Jun 2016
- Health and Human S · $314K
- First Form D · Jul 2024
- $1M · 1st Form D
- Awards before first raise
- 19 awards
An association in public records, not a cause or a prediction.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#186 · top 36%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Upendra MarathiResearcherExecutive Officer, DirectorLinked by $11.5M in grants as PI
- Joseph BailesDirectorNamed in SEC Form D filings
- Kala MarathiDirectorNamed in SEC Form D filings
- Robert A. BentExecutive OfficerNamed in SEC Form D filings
- Stephen A. BentExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 5- GrantedIntegrin Agonists Or Activating Compounds And Methods For Making And Using SameUSPTOUS 12,109,263
- PendingMethods For Administering Compositions Including Integrin Agonists Having Anti-tumor ActivityUSPTOApplication 17080195
- PendingCompositions And Methods To Improve The Homing And Grafting Of Hematopoetic Stem CellsUSPTOApplication 14621112
Show all 5 patent records
- Integrin Agonists Or Activating Compounds And Methods For Making And Using SameOct 8, 2024 · US 12,109,263Granted
- Methods For Administering Compositions Including Integrin Agonists Having Anti-tumor ActivityMay 20, 2021 · Application 17080195Pending
- Compositions And Methods To Improve The Homing And Grafting Of Hematopoetic Stem CellsSep 10, 2015 · Application 14621112Pending
- Novel Lipid-based Small Molecule Integrin Receptor-ligand Agonist Adjuvants Carrier Compositions, Integrin Agonist Adjuvant Pharmaceutical Compositions Therefrom, And Methods For Making And Using SameApplication 63337960Pending
- Integrin Agonist Or Activating Compounds And Methods For Making And Using SameApplication 63076595Pending
Related companies, and why
- NOVILYTIC, LLCSimilar federal contract value in Biotech · null in contracts
- OPTIKIRA, LLCSimilar federal contract value in Biotech · null in contracts
- AMERICAN LIFE SCIENCE PHARMACEUTICALS, INC.Similar federal contract value in Biotech · null in contracts
- AyuVis Research, Inc.Similar federal contract value in Biotech · null in contracts
- EPOCH BIOTECH, LLCSimilar federal contract value in Biotech · null in contracts
- Galera Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .